首页> Journal of controlled release : official journal of the Controlled Release Society> Lipid nanomedicine simultaneously inhibits BRD4/PI3K and MDM2/XIAP signaling pathways for effective treatment of Medulloblastoma.

Lipid nanomedicine simultaneously inhibits BRD4/PI3K and MDM2/XIAP signaling pathways for effective treatment of Medulloblastoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Bharti,Sethi

第一单位： Department of Pharmaceutical Sciences, The University of Nebraska Medical Center, Omaha, NE 68198, USA.

作者： Bharti,Sethi ^[1] ; Aditya,Gupta ^[1] ; Qiaoyu,Pan ^[1] ; Sohan,Mahto ^[1] ; Ajaykumar,Chittipolu ^[1] ; Helen,Erickson ^[1] ; Virender,Kumar ^[1] ; Yanfei,Chen ^[2] ; Zhongzhi,Wu ^[2] ; Yuxiang,Dong ^[1] ; Wei,Li ^[2] ; Donald R,Ronning ^[1] ; Donald W,Coulter ^[3] ; Ram I,Mahato ^[4]

作者单位： Department of Pharmaceutical Sciences, The University of Nebraska Medical Center, Omaha, NE 68198, USA. ^[1] Department of Pharmaceutical Sciences, The University of Tennessee Health Science Center, Memphis 38105, USA. ^[2] Department of Pediatrics, The University of Nebraska Medical Center, Omaha, NE 68198, USA. ^[3] Department of Pharmaceutical Sciences, The University of Nebraska Medical Center, Omaha, NE 68198, USA. Electronic address: ram.mahato@unmc.edu. ^[4]

关键词 BRD4 JW475A LNPs MDP5 Medulloblastoma PI3K RVG-peptide